Remember Covid-19? When billions were vulnerable because their national health systems lacked life-saving vaccines?
This gap prompted the WHO and Medicines Patent Pool to launch the mRNA Technology Transfer Programme, building vaccine manufacturing capability in low- and middle-income countries (LMICs).
Flow was proud to take this story of investment in life-saving medical technology and capability to the world. At its heart was a simple principle: where a person lives, and how wealthy their country is, should not determine their access to life-saving health technologies.
Share
We value your privacy
We use cookies to enhance your browsing experience, serve personalised content, and analyse our traffic. By clicking "Accept All", you consent to our use of cookies.
Customise Consent Preferences
This site uses cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.
The cookies categorised as Necessary are stored on your browser as they are essential for enabling the basic functionalities of the site. We also use third-party cookies that help us analyse how you use this website. These cookies will only be stored in your browser with your prior consent.
